Clinical trial NCT06827002: Effect of Aqueous Extracts of Cissus Quadrangularis and Dichrostachys Glomerata on GLP-1 Concentration and DPP-4 Activity in Overweight and Obese Adults
Official title: Cissus Quadrangularis (CQR-300®) and Dichrostachys Glomerata (Dyglomera®) Extracts Increase GLP-1 Levels and Inhibit Dipeptidyl Phosphate-4 Activity in Healthy Overweight and Obese Adults
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
PHASE2
Conditions: Obesity and Overweight
Appetite Regulation
Keywords: Natural Products
GLP-1
DDP-4 Inhibitors
Obesity management
Appetite regulation
CQR-300®
Dyglomera®
Lead sponsor: University of Yaounde 1
Sponsor class: OTHER
First posted: 2025-02-14
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: The study involves Ninety (90) overweight or obese participants (25 ≥ BMI ≤ 30), randomly divided into three groups: the placebo group, Dyglomera® group, and CQR-300® group.
Primary purpose: TREATMENT

Brief summary: Obesity is a global health crisis affecting over 2.3 billion individuals worldwide. This prospective study aims to evaluate the comparative effects of Cissus quadrangularis (CQR-300) and Dichrostachys glomerata (Dyglomera™) extracts on obesity-related parameters, focusing on their impact on glucagon-like peptide-1 (GLP-1) levels and dipeptidyl peptidase-4 (DPP-4) enzyme activity in obese subjects. Parameters such as GLP-1 levels, DPP-4 activity, food intake, body weight, blood lipids, fasting blood glucose, and visceral fat mass will be measured at baseline and various intervals.

In our previous pre-clinical trial involving 18 adult male Wistar rats (150-200 g), randomly divided into three groups: a control group fed a normal diet, and two treatment groups receiving Dyglomera™ (400 mg/kg) or CQR-300 (300 mg/kg) alongside a normal diet, the results demonstrated that both Dyglomera™ and CQR-300 significantly increased GLP-1 levels and inhibited DPP-4 activity compared to the control group. These effects were associated with reduced food intake, body weight, and fasting blood glucose levels. Additionally, both extracts positively modified blood lipid profiles, with significant changes in HDL, LDL, and triglyceride levels. The findings suggest that Dyglomera™ and CQR-300 exert their anti-obesity effects through mechanisms involving GLP-1 enhancement and DPP-4 inhibition, offering potential therapeutic pathways for weight management and metabolic health.

This prospective study aims to provide clinical evidence supporting the use of these plant extracts in addressing obesity and its related complications.

Detailed description: Obesity is a health burden affecting over 2.3 billion people of all ages globally. The development and progression of obesity involve a complex pathogenesis, and several drugs have been developed to target these pathways. In recent years, dipeptidyl peptidase-4 (DPP-4) inhibitors or gliptins, such as sitagliptin, saxagliptin, and vildagliptin, have been considered as a viable obesity management option. Gliptins inhibit DPP-4, an enzyme known to deactivate the GLP-1 hormone, contributing to the development and progression of obesity and other metabolic diseases. GLP-1 is one of the important incretin hormones secreted in the L-cells of the gut for the maintenance of blood sugar homeostasis. It exhibits other pleiotropic effects through its receptors in the liver, brain, and stomach to delay gastric emptying, reduce appetite, and induce significant weight loss. In healthy individuals, GLP-1 has a half-life of \>2 minutes due to the activities of DPP-4 . Some studies have observed higher DPP-4 levels in obese individuals, further reducing the incretin effects of GLP-1. Gliptins are primarily invented to manage type 2 diabetes. However, their weight loss effects are quite significant, presenting as a potent management option for obesity.

Synthetically produced drugs are often associated with side effects and contraindications. For conditions such as obesity, patients often require unique management options due to sensitivity and the high likelihood of comorbidities. For instance, obese individuals are more vulnerable to pancreatitis and pancreatic cancer, whereas gliptins are associated with a high incidence of acute pancreatitis. Gliptins also present other side effects such as upper respiratory infections, headache, urinary tract infections, arthralgia, and in severe cases, Stevens-Johnson syndrome. Cost-wise, gliptins are considerably expensive. The current FDA-approved gliptins are intended for the management of diabetes. Prescribing them for obesity may lead to higher demand and prices as well as scarcity. Hence, there is a need for a wider range of safe, cost-effective, and potent alternatives.

Natural products continue to emerge as potential drug leads for several metabolic disease conditions due to their potency and low toxicity. Dyglomera™ (Dichrostachys glomerata), a popular Cameroonian spice, and CQR-300 (Cissus quadrangularis), an ornamental and medicinal plant growing in Africa and Asia, have shown tremendous effects on weight loss. A recent study showed that Dyglomera™ induced 22.85% weight loss in 60 subjects in 12 weeks. In a double-blind placebo-controlled study involving 35 subjects, CQR-300 reduced body fat by 12.8% in 8 weeks. The mechanism of these two extracts is not fully understood. It has been proposed that Dyglomera™ and CQR-300 are anorectic. Some studies suggested that Dyglomera™ and CQR-300 reduced food intake through increased adiponectin secretion and the AMPK pathway.

Additionally, CQR-300 was shown to boost serotonin levels. Serotonin has received much attention in weight loss research in the past. It has been implicated for its appetite-suppressing effect on the arcuate nucleus hypothalamus, a region responsible for food intake and energy expenditure.

Up to the present, no study has investigated the effect of Dyglomera™ or CQR-300 on GLP-1 or DPP-4 levels. Hence, this study aims to evaluate the efficacy of Dyglomera™ and CQR-300 as potent alternatives to gliptins in obesity management.

Eligibility criteria: Inclusion Criteria:

* Healthy males and non-pregnant/non-lactating females
* Participants aged 18 to 65 years old
* Participants with BMI between 25 and 30 kg/m²
* Participants willing to comply with the study protocol

Exclusion Criteria:

* Participants younger than 18 years or older than 65 years
* Participants not available for the study period
* Morbid obesity (BMI \> 34.9 kg/m²)
* Diabetes mellitus requiring daily insulin management
* Pregnancy or breastfeeding
* Active infection
* Systemic diseases, including HIV/AIDS, Active hepatitis, Clinical signs of active malignancy within the past 5 years
* Use of any medication or natural health product that might affect the parameters of interest in this study

Primary outcomes:
measure: Effect of Dyglomera® and CQR-300® on participants GLP-1 level
timeFrame: Baseline (Week 0), Week 4, Week 8, and Week 12
measure: Effect of Dyglomera® and CQR-300® on participants BMI
timeFrame: Baseline (Week 0), Week 4, Week 8, and Week 12
measure: Effect of Dyglomera® and CQR-300® on participants Fasting blood glucose
timeFrame: Baseline (Week 0), Week 4, Week 8, and Week 12
measure: Effect of Dyglomera® and CQR-300® on participants DPP4 activity
timeFrame: Baseline (Week 0), Week 4, Week 8, and Week 12
measure: Effect of Dyglomera® and CQR-300® on participants Lipid Profile
timeFrame: Baseline (Week 0), Week 4, Week 8, and Week 12
measure: Effect of Dyglomera® and CQR-300® on participants Body Fat percentage
timeFrame: Baseline (Week 0), Week 4, Week 8, and Week 12
measure: Effect of Dyglomera® and CQR-300® on participants Body weight
timeFrame: Baseline (Week 0), Week 4, Week 8, and Week 12
Secondary outcomes:
measure: Effect of Dyglomera® and CQR-300® on participants' energy Intake
timeFrame: Week 12
Other outcomes:
Locations:
city: Yaoundé
country: Cameroon
facility: University of Yaounde 1
state: Centre
Study officials:
affiliation: University of Yaounde 1
name: Julius E Oben, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972 Jun;18(6):499-502. No abstract available.
citation: Youovop J, Takuissu G, Mbopda C, Nwang F, Ntentié R, Mbong M, Azantsa B, Singh H, Oben J. The effects of Dyglomera® (Dichrostachys glomerata extract) on body fat percentage and body weight: a randomized, double-blind, placebo-controlled clinical trial. Functional Foods in Health and Disease 2023, 13: 334-346.
citation: Filipova EP, Uzunova KH, Vekov TY. Comparative analysis of therapeutic efficiency and costs (experience in Bulgaria) of oral antidiabetic therapies based on glitazones and gliptins. Diabetol Metab Syndr. 2015 Jul 16;7:63. doi: 10.1186/s13098-015-0059-7. eCollection 2015.
citation: Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse Effects of GLP-1 Receptor Agonists. Rev Diabet Stud. 2014 Fall-Winter;11(3-4):202-30. doi: 10.1900/RDS.2014.11.202. Epub 2015 Feb 10.
citation: Tkac I, Raz I. Combined Analysis of Three Large Interventional Trials With Gliptins Indicates Increased Incidence of Acute Pancreatitis in Patients With Type 2 Diabetes. Diabetes Care. 2017 Feb;40(2):284-286. doi: 10.2337/dc15-1707. Epub 2016 Sep 22.
citation: Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013 Jun;144(6):1252-61. doi: 10.1053/j.gastro.2013.01.068.
citation: Valerio CM, de Almeida JS, Moreira RO, Aguiar LBS, Siciliano PO, Carvalho DP, Godoy-Matos AF. Dipeptidyl peptidase-4 levels are increased and partially related to body fat distribution in patients with familial partial lipodystrophy type 2. Diabetol Metab Syndr. 2017 Apr 24;9:26. doi: 10.1186/s13098-017-0226-0. eCollection 2017.
citation: Ahren B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res. 2004 Nov-Dec;36(11-12):867-76. doi: 10.1055/s-2004-826178.
citation: van Bloemendaal L, Ten Kulve JS, la Fleur SE, Ijzerman RG, Diamant M. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol. 2014 Mar 7;221(1):T1-16. doi: 10.1530/JOE-13-0414. Print 2014 Apr.